By Alena Jiraskova, Anneli Andersson, Jana Sponarova, and Philip Zimmermann
© NEBION AG. April 15, 2019
Non-alcoholic fatty liver disease (NAFLD) is a chronic, progressive liver disease. The onset of the disease is highly associated with obesity, insulin resistance and dyslipidemia. Without intervention, the disease can progress to non-alcoholic steatohepatitis (NASH), and via fibrosis and cirrhosis, to end-stage liver disease and hepatocellular carcinoma (HCC). New technologies and more research efforts are needed to develop crucial stage-specific diagnosis, effective treatment decisions and translational models. In this study, we used GENEVESTIGATOR® for NASH mouse model characterization and biomarker validation. GENEVESTIGATOR® is an analysis tool and database, containing high quality curated gene expression data. It allows the user to mine the data of thousands of experiments simultaneously, to identify genes having a very specific profile or indications associated with the transcriptional activity of selected genes.